{"id":"NCT02939287","sponsor":"Rush University Medical Center","briefTitle":"Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan","officialTitle":"Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-23","primaryCompletion":"2021-12-30","completion":"2022-12-01","firstPosted":"2016-10-20","resultsPosted":"2024-01-22","lastUpdate":"2024-10-22"},"enrollment":52,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Nausea","Vomiting"],"interventions":[{"type":"DRUG","name":"o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1","otherNames":["Emend"]},{"type":"DRUG","name":"Olanzapine10 mg orally daily on Days -1,0,+1 and +2","otherNames":["Zyprexa"]},{"type":"DRUG","name":"Aprepitant plus Olanzapine","otherNames":["Emend","Zyprexa"]}],"arms":[{"label":"Aprepitant","type":"ACTIVE_COMPARATOR"},{"label":"Olanzapine","type":"EXPERIMENTAL"},{"label":"Aprepitant plus olanzapine","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to help answer the following research question:\n\n* Whether administration of an aprepitant containing regimen, an olanzapine containing regimen or regimen containing both will prevent nausea and vomiting better for patients undergoing an autologous stem cell transplant with melphalan chemotherapy. Both of these medications are approved by the United States Food and Drug Administration (FDA) for nausea and vomiting.\n* Participants will be randomly assigned to one of the 3 treatment groups:\n\n  * Arm A: aprepitant containing anti-emetic therapy\n  * Arm B: olanzapine containing anti-emetic therapy\n  * Arm C: Aprepitant plus olanzapine containing anti-emetic therapy","primaryOutcome":{"measure":"Complete Response (CR)","timeFrame":"within 120 hours following melphalan administration; no emesis and no rescue therapy within 120 hours of melphalan administration (within 120 hours following last day of melphalan administration at baseline)","effectByArm":[{"arm":"Aprepitant","deltaMin":4,"sd":null},{"arm":"Olanzapine","deltaMin":11,"sd":null},{"arm":"Aprepitant Plus Olanzapine","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["21947834","22024310","20935058","11130251","11781617","20505956","20838387","21996238","22863840","11997204","11711053","16983116","25225424","12827483"],"seeAlso":["https://mascc.org"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":14},"commonTop":[]}}